Iradimed (IRMD) CFO John Glenn Sells $214K of Stock

John Glenn, the CFO of IRMD, sold 2,319 shares of the company on June 20, 2026, at an average price of $92.20 per share. This transaction brought in a total of $213,811. The sale was not part of a pre-arranged trading plan.

Other Institutional Activity in IRMD

In recent institutional activity, BlackRock, Inc. reduced its holdings in IRMD by 34,212 shares, leaving it with 967,787 shares valued at about $93.16 million, a 3.4% decrease. Renaissance Technologies LLC also trimmed its stake by 15,700 shares, holding 440,712 shares worth approximately $42.42 million, reflecting a similar 3.4% reduction. Copeland Capital Management, LLC cut its position by 53,225 shares to 359,325 shares, valued at around $34.59 million, marking a 12.9% decrease. Meanwhile, Vanguard Capital Management LLC opened a new position with 358,620 shares valued at $34.52 million. Kayne Anderson Rudnick Investment Management LLC increased its stake by 16,087 shares to 349,316 shares, a 4.8% increase, valued at $33.63 million.

Iradimed Corporation Stock Up 12.5%

Shares of IRMD traded near $91.69 on Tuesday. The company has been the focus of various institutional investors, with significant movements in holdings noted. The stock's price reflects ongoing market dynamics and investor sentiment.

Insider Buying and Selling at Iradimed Corporation

On June 20, 2026, IRMD's CFO John Glenn sold 2,319 shares at an average price of $92.20, totaling $213,811. Other notable insider activity includes Hilda Frederique Scharen-Guivel, who sold 3,000 shares at $95.00 on June 4, 2026. Additionally, CEO Roger Susi sold 2,500 shares on June 1 and May 27, 2026, at average prices of $90.60 and $91.95, respectively, under planned trading agreements.

Analysts Set New Price Targets

Roth MKM reiterated a 'buy' rating for IRMD on February 14, 2025, with a price target of $72. Lake Street also maintained a 'buy' rating on June 17, 2024, with a $60 target. These ratings reflect continued confidence in IRMD's market position and growth potential.

Bottom Line

John Glenn's recent sale of IRMD shares is a notable insider transaction, reflecting his personal financial strategy rather than a signal of company performance. Institutional investors have been actively adjusting their positions, illustrating diverse strategies and outlooks on IRMD's future. While the stock price fluctuates, analyst ratings remain positive, underscoring the potential seen by market experts.